Dataset opportunity
Duchefa Biochemie — 监管记录数据集机会
Duchefa Biochemie 持有的中等监管记录数据集,可用于监管 RAG 和合规性 Copilots。
Score
70
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
收购
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球监管信息管理系统市场 = 2024 年为 22 亿美元,复合年增长率为 10.9%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- ✨Signal
维护完整的原材料可追溯系统和 ISO 9001/GMP 标准
source ↗
Profile
Dataset profile
Type
监管记录数据集
Modality
文本
Sector
healthcare
Volume
中等
Freshness
定期
Rarity
高(专有)
Accessibility
部分
Legal
公司所有 — 许可干净
Buyer persona
RegTech 和合规性 AI 供应商
Duchefa Biochemie 持有一个专门的监管记录数据集,其文本模态包含详细的业务记录、工业数据和监管备案。这包括专有配方、LIMS 的质量控制日志以及历史提交文件,使其成为训练监管 RAG 系统以应对复杂的合规性和生物化学查询的极其丰富的来源。
该数据的价值体现在全球监管信息管理市场,该市场在 2024 年的估值为22 亿美元,预计将以 10.9% 的复合年增长率增长。虽然访问需要通过 NDA 来处理专有配方,但这种工业数据的稀有性和高价值性为人工智能买家提供了显著的竞争优势,证明了协商访问的合理性。⚠ 尽职调查(有价值的数据,可协商访问):定制培养基的专有配方通常受与客户的保密协议约束;数据可能存储在实验室信息管理系统 (LIMS) 和质量控制日志中 · 公司:独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Duchefa Biochemie 持有深入的、专有的内部监管记录数据集,用于指导特种生化产品的生产。这些文件详细说明了对GMP 和 ISO 9001 等关键标准的遵守情况,包括完整的原材料可追溯性。对于 RegTech 和合规性 AI 供应商而言,该数据集是构建和微调监管 RAG 系统的稀有资产,这是在快速增长的 22 亿美元全球监管信息管理市场中至关重要的能力。
See dimension details ↓- Dataset Specificity78
主导的“监管”,医疗保健行业,2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适合监管 RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand85
人工智能买家需求旺盛,这得益于全球监管信息管理市场的显著增长,该市场正以 10.9% 的复合年增长率扩张。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility50
受限/未知
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility44
低难度,独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型,3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License92
所有权=公司所有,许可=干净
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 个数据需求信号(1 种类型)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ 良好目标 — Duchefa Biochemie 是用于植物组织培养的生化产品的生产商和批发商,其生产过程会产生监管和生产数据作为副产品,并且似乎不进行销售。问题:确切的员工人数未公开,因此中小企业身份是根据公司描述和运营范围进行的估算。
- Deep Qualification90
⚠ 需要审查 — 目标是一个拥有连贯监管数据的持有者,但所有权混合且许可受到定制配方的限制。至关重要的是,其数据领域(植物科学)与指定的细分市场(医疗设备)不匹配。[许可受限;实体不持有细分市场的特征数据:目标数据与植物生物技术和植物病理学法规相关,而不是与细分市场定义的“医疗设备监管合规性”。]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
这些证据证实了 300 多种定制培养基配方的详细产品规格和制造数据,为相关的监管备案提供了重要的运营背景。
business_records
这是内部质量控制文档的直接证明,展示了完整的原材料可追溯性系统以及对全球 GMP 和 ISO 9001 标准的遵守情况。
Regulatory records
这些证据指向一个专门的监管文本语料库,侧重于特定的生命科学应用,包括植物病理学和种子健康测试,对于在特定行业垂直领域训练模型很有价值。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Duchefa Biochemie Regulatory Records — a Moderate regulatory records dataset (Text modality) in the healthcare domain. Primary AI use-case: Regulatory RAG. Market signal: Global Regulatory Information Management system market = $2.2 billion in 2024, CAGR 10.9% (source: Global Market Insights, Inc.). Investment score 70.0/100 (confidence 0.49). Recommended action: Acquire.
From the marketplace
Explore live data opportunities
Georgebakershipping — 法规记录数据集机会
View opportunity →医疗保健Starseq — 医疗影像数据集机会
View opportunity →医疗保健Icentia — 医学影像数据集机会
View opportunity →